Patients on adalimumab should not be given any of the 'live' vaccines such as those for polio, rubella (German measles) and yellow fever, although inactivated vaccines are safe.
- Fully human monoclonal anti-TNF-alpha antibody
- Assuming 26 doses per year, the annual cost of adalimumab is £9155.64
- Blocks stimulation of TNF receptors and down-regulates inflammatory response
- Adalimumab does not work immediately and it may be 3-12 weeks before benefit.
- Profile similar to Infliximab
- Rheumatoid arthritis, Severe psoriasis or Psoriatic arthritis
- Ankylosing spondylitis, Crohn's disease. Juvenile idiopathic arthritis.
- Adalimumab is administered subcutaneously as a 40 mg dose every other week
Dose range: It must be stored in a refrigerator (at 2-8°C).
|Adalimumab (RA)||40 mg||Every 2 weeks||SC|
|Adalimumab (Crohn's )||Start 160 mg then 80 mg and then 40 mg once weekly||Every 2 weeks||SC|
- Respiratory tract infections, leukopenia, anaemia, increased lipids
- Headache, abdominal pain, nausea and vomiting
- Elevated liver enzymes, rash, musculoskeletal pain and injection site reaction.
- Adalimumab is contraindicated in people with active tuberculosis or other severe infections, and people with moderate or severe heart failure
- Active tuberculosis should be treated with standard treatment for at least 2 months before starting adalimumab
- Patients on adalimumab should not be given any of the 'live' vaccines such as those for polio, rubella (German measles) and yellow fever, although inactivated vaccines are safe.
- Pharmacologic inhibition of tumour necrosis factor-α (TNF-α) for the treatment of chronic inflammatory disease such as Crohn’s or psoriasis increases the risk of developing active tuberculosis among those with latent infection.